GSK plc

GSK plc AAQS

The The AAQS of GSK plc (GSK.L) as of Nov 2, 2026 is 7. In the previous year, The AAQS was 7.00 — a change of 0.00% (lower).

AAQS

7

YoY

0.00%

Last updated:

GSK plc has a current AAQS of 7.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock GSK plc in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The GSK plc AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
7.00 GBP
Jan 1, 2019
7.00 GBP
Jan 1, 2020
7.00 GBP
Jan 1, 2021
7.00 GBP
Jan 1, 2022
7.00 GBP
Jan 1, 2023
7.00 GBP
Jan 1, 2024
7.00 GBP
Jan 1, 2025
7.00 GBP
The GSK plc AAQS history
YEARAAQSYoY
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
7—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

The AAQS of GSK plc is 7 in 2025.

On Eulerpool you can find the complete historical development of The AAQS GSK plc since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — GSK plc

All Key Metrics — GSK plc